Search
Ombitasvir
go.drugbank.com/drugs/DB09296ApprovedInvestigationalIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Ombitasvir as a first line … Depending on the genotype, Ombitasvir is often used in combination with other antivirals such as [DB09183], [DB09297], [DB00503], and [DB00811] with the intent to cure, or achieve a sustained virologic
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnProsomastatin is further process into two active forms, somatostatin-14 (SST-14) and somatostatin-28 (SST-28), an extended SST-14 sequence to the N-terminus [A20384]. … Somatostatin has been used in the clinical setting for the diagnosis of acromegaly and gastrointestinal tract tumours.
Triflupromazine
go.drugbank.com/drugs/DB00508ApprovedVet approvedA phenothiazine used as an antipsychotic agent and as an antiemetic.
Ledipasvir
go.drugbank.com/drugs/DB09027ApprovedIts use has also proven successful in the treatment of HCV in patients co-infected with HIV [A19627]. … It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of HCV.
Quazepam
go.drugbank.com/drugs/DB01589ApprovedIllicitIt was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. … [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other
Gadopiclenol
go.drugbank.com/drugs/DB17084ApprovedInvestigationalGadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. … [A254002,A254017] In September 2022, the use of gadopiclenol was approved by the FDA.
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key resistance mechanism to MAPK inhibitors, facilitating tumor cell proliferation and survival in
Synonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamideCarfilzomib
go.drugbank.com/drugs/DB08889ApprovedInvestigationalCarfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. … FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Acetylcholine
go.drugbank.com/drugs/DB03128ApprovedInvestigationalIt is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications. … Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in
Products: Miochol E, MIOCHOL ESitaxentan
go.drugbank.com/drugs/DB06268ApprovedWithdrawnIn 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity. … Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008.